Viva Biotech Holdings (1873) AI Stock Analysis

• Market Cap: HK$5.45B
• Dividend Yield: N/A
• Average Volume (3M): 17.70M
• Price to Earnings (P/E): 28.6
• Beta (1Y): 2.31
• Revenue Growth: -8.11%
• EPS Growth: N/A
• Country: HK
• Employees: 2,063
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.05
• Shares Outstanding: 2,128,434,300
• 10 Day Avg. Volume: 12,076,500
• 30 Day Avg. Volume: 17,697,213
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$3.00
• Price Target Upside: 20.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: HK$3.00 ▲(20.00% Upside)

The overall stock score is driven by strong technical indicators, suggesting bullish momentum, which is the most significant factor. However, the financial performance is mixed, with concerns about cash flow stability and profitability. The valuation appears high, which could limit upside potential. The absence of earnings call and corporate events data means these factors do not influence the score.

Viva Biotech Holdings Business Overview & Revenue Model

Company Description

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins. In addition, the company offers contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs) and intermediates; and trades in APIs, intermediates, and formulations, as well as equity for service. Further, it provides research service; laboratory rental services; and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.

How the Company Makes Money

Viva Biotech Holdings generates revenue primarily through its contract research organization (CRO) services. The company offers structure-based drug discovery (SBDD) services, which involve various stages of drug development including target identification, hit identification, lead optimization, and preclinical evaluations. Viva Biotech's key revenue streams include fees for its CRO services provided to pharmaceutical and biotechnology companies, who rely on Viva's expertise to accelerate their drug discovery and development processes. Additionally, the company may earn income through strategic partnerships and collaborations, where they might receive milestone payments or royalties based on the success of the drugs developed using their services. These collaborations often enhance their revenue potential and market reach.

Viva Biotech Holdings Financial Statement Overview

Summary

Viva Biotech Holdings exhibits a mixed financial performance. While profitability metrics show signs of recovery, inconsistencies in revenue and net income present challenges. The balance sheet remains robust with a solid equity base and manageable debt levels. However, cash flow volatility and recent declines in operating cash flow suggest potential liquidity concerns. The company should focus on stabilizing cash generation and enhancing profitability to strengthen its financial health.

Income Statement

The company's revenue has shown volatility over the years, with a decrease from 2022 to 2024. Gross profit margins have remained strong, averaging around 35%. Net income has improved in 2024 compared to the losses in previous years, signaling a recovery. However, net profit margins have been inconsistent, indicating potential profitability challenges.

Balance Sheet

The company has a stable equity position with a debt-to-equity ratio of 0.34 in 2024, lower than the previous year, indicating manageable leverage. The equity ratio remains above 50%, highlighting a solid financial foundation. However, the decrease in cash reserves over time suggests potential liquidity management issues.

Cash Flow

Operating cash flow has fluctuated significantly, with a concerning drop to zero in 2024. This instability raises questions about the company's ability to generate consistent cash flow from operations. The lack of free cash flow growth further indicates potential challenges in maintaining positive cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.99B	2.16B	2.38B	2.10B	696.96M
Gross Profit	687.40M	738.43M	815.68M	650.98M	304.87M
EBITDA	428.00M	391.01M	-89.04M	369.94M	-223.89M
Net Income	167.29M	-116.11M	-528.48M	287.55M	-386.88M
Balance Sheet
Total Assets	7.05B	7.45B	7.92B	8.04B	8.15B
Cash, Cash Equivalents and Short-Term Investments	941.58M	1.04B	678.57M	800.95M	2.36B
Total Debt	1.28B	1.90B	2.82B	2.65B	2.97B
Total Liabilities	3.23B	3.76B	4.32B	4.13B	4.40B
Stockholders Equity	3.80B	3.69B	3.60B	3.91B	3.76B
Cash Flow
Free Cash Flow	182.32M	195.57M	136.72M	-487.35M	-549.44M
Operating Cash Flow	373.99M	383.40M	386.05M	77.83M	43.18M
Investing Cash Flow	185.90M	439.17M	-372.80M	-868.84M	-3.85B
Financing Cash Flow	-657.76M	-429.50M	-143.20M	-653.16M	5.31B

Viva Biotech Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Neutral. The current price of 2.5 is below the 20-day moving average (MA) of 2.63, above the 50-day MA of 2.21, and above the 200-day MA of 1.56, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 50.01 is Neutral, neither overbought nor oversold. The STOCH value of 46.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1873.

Viva Biotech Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2696	70 Outperform	42.20B	47.02	27.23%	―	2.57%	18.79%
1873	60 Neutral	HK$5.45B	28.64	4.45%	―	-8.11%	―
2157	57 Neutral	13.49B	-64.92	-58.53%	―	240.05%	-140.09%
1877	54 Neutral	44.28B	-26.35	-21.86%	―	44.21%	46.11%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Viva Biotech Holdings Corporate Events

Viva Biotech Holdings Successfully Passes All Resolutions at Annual General Meeting

Viva Biotech Holdings announced that all resolutions were passed at its Annual General Meeting held on June 12, 2025. The resolutions included the adoption of financial statements, re-election of directors, authorization of director remuneration, re-appointment of auditors, and mandates related to share capital management. The successful passing of these resolutions reflects shareholder confidence and supports the company’s strategic direction, potentially impacting its operational and market positioning positively.

Viva Biotech Clarifies Details on Connected Transaction with Nanjing Entities

Viva Biotech Holdings has announced a supplemental update regarding a connected transaction involving the establishment of a limited partnership fund. The update clarifies that several Nanjing-based entities involved in the joint venture are controlled by the Nanjing Jiangbei New Area Management Committee, a governmental body. This announcement reinforces the company’s strategic positioning and potential influence in the biotechnology sector through governmental collaboration.

Viva Biotech Enters Joint Venture to Launch Pharmaceutical Investment Fund

Viva Biotech Holdings, through its subsidiary Hangzhou Viva Zongchen, has entered into a Joint Venture Agreement to establish a new Fund focused on private equity investments in the pharmaceutical industry. The Fund, which has a term of seven years, will concentrate on early-stage development projects and technological innovation in life sciences. Hangzhou Viva Zongchen will invest RMB25.0 million as a limited partner. This strategic move positions Viva Biotech to leverage emerging opportunities in the pharmaceutical sector, potentially enhancing its industry standing and offering growth prospects for stakeholders.